These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 5326104)

  • 1. Serological studies of types A, B, and E botulinal toxins by passive hemagglutination and bentonite flocculation.
    Johnson HM; Brenner K; Angelotti R; Hall HE
    J Bacteriol; 1966 Mar; 91(3):967-74. PubMed ID: 5326104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological specificity of type E botulinal toxin.
    Johnson HM; Smith BG; Lewis KH
    Proc Soc Exp Biol Med; 1971 Jul; 137(3):973-6. PubMed ID: 4997865
    [No Abstract]   [Full Text] [Related]  

  • 3. [Use of the passive hemagglutination inhibition reaction for the purpose of determining the antigenic activity of anatoxins in vitro].
    Vorontsov IV; Moshiashvili IIa; Severtsova MK; Besova SA
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Apr; (4):62-6. PubMed ID: 375637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on immunity to toxins of Clostridium botulinum. VII. Purification and detoxification of trypsin-activated type E toxin.
    FIOCK MA; YARINSKY A; DUFF JT
    J Bacteriol; 1961 Jul; 82(1):66-71. PubMed ID: 13699727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro acetylcholinesterase inhibition by type A botulinum toxin.
    Marshall R; Quinn LY
    J Bacteriol; 1967 Oct; 94(4):812-4. PubMed ID: 4860916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of the reversed passive hemagglutination in detection of Clostridium botulinum type A, B, and E toxin (author's transl)].
    Sonnenschein B
    Zentralbl Bakteriol Orig A; 1978 Apr; 240(2):221-34. PubMed ID: 207051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REVERSED PASSIVE HAEMAGGLUTINATION SYSTEMS FOR THE ESTIMATION OF TETANUS TOXINS AND ANTITOXINS.
    COOK RJ
    Immunology; 1965 Jan; 8(1):74-80. PubMed ID: 14245316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinal toxin and toxoid as antigens.
    Heimach RC; Champion LA; Sugiyama H
    Proc Soc Exp Biol Med; 1970 Oct; 135(1):151-4. PubMed ID: 4920940
    [No Abstract]   [Full Text] [Related]  

  • 9. Enterotoxin B: serological assay in cultures by passive hemagglutination.
    Johnson HM; Hall HE; Simon M
    Appl Microbiol; 1967 Jul; 15(4):815-8. PubMed ID: 4963442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of type A botulinal toxin assays that use antitoxin to crystalline toxin.
    Sugiyama H; Oishi I; Dasgupta BR
    Appl Microbiol; 1974 Feb; 27(2):333-6. PubMed ID: 4856714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Titration of cholera antitoxin in human sera by microhemagglutination with formalinized erythrocytes.
    Hochstein HD; Feeley JC; DeWitt WE
    Appl Microbiol; 1970 May; 19(5):742-5. PubMed ID: 5463574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Titration of Clostridium oedematiens antitoxin by reversed passive haemagglutination.
    Cook RJ
    Immunology; 1965 Sep; 9(3):249-54. PubMed ID: 5838198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on immunity to toxins of Clostridium botulinum. VI. Purification and detoxification of type D toxin and the immunological response to toxoid.
    CARDELLA MA; DUFF JT; WINGFIELD BH; GOTTFRIED C
    J Bacteriol; 1960 Mar; 79(3):372-8. PubMed ID: 13807649
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of antibody to each component of Clostridium botulinum type E progenitor toxin.
    Sakaguchi G; Sakaguchi S
    Jpn J Med Sci Biol; 1973 Dec; 26(5):187-95. PubMed ID: 4601357
    [No Abstract]   [Full Text] [Related]  

  • 15. The lack of identity between hemagglutinin and the toxin of type A botulinal organism.
    LAMANNA C; LOWENTHAL JP
    J Bacteriol; 1951 Jun; 61(6):751-2. PubMed ID: 14850434
    [No Abstract]   [Full Text] [Related]  

  • 16. Determination of botulinum toxin type by the reaction of indirect hemagglutination inhibition.
    Reiss J; Wojtyła B
    Arch Immunol Ther Exp (Warsz); 1981; 29(1):97-108. PubMed ID: 7025794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of Clostridium botulinum toxoid. II. Type B toxoid.
    VOROB'EV AA; VASIL'EV NN; ENICHEV VM; PATRIKEYEV GT; SHEVELEV VM; ZYBIN VD; KORNEV IS; ANAN'EVA EP
    Zh Mikrobiol Epidemiol Immunobiol; 1961; 32():1851-6. PubMed ID: 14040098
    [No Abstract]   [Full Text] [Related]  

  • 18. Toxoid of Clostridium botulinum type F: purification and immunogenicity studies.
    Hatheway CL
    Appl Environ Microbiol; 1976 Feb; 31(2):234-42. PubMed ID: 793522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple method for purification of type E botulinal toxin from the precursor extract of the bacterial cells.
    SAKAGUCHI G; SAKAGUCHI S
    Jpn J Med Sci Biol; 1961 Dec; 14():243. PubMed ID: 14496146
    [No Abstract]   [Full Text] [Related]  

  • 20. Cross reaction in reversed passive hemagglutination between Clostridium botulinum type A and B toxins and its avoidance by the sue of anti-toxic component immunoglobulin isolated by affinity chromatography.
    Sakaguchi G; Sakaguchi S; Kozaki S; Sugii S; Oishi I
    Jpn J Med Sci Biol; 1974 Jun; 27(3):161-72. PubMed ID: 4604281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.